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Outcomes following treatment of in-stent restenosis
DEB DES Total p
MACE 25 (26%) 21 (24%) 46 (25%) 0.80
Death 15 (16%) 6 (7%) 21 (12%) 0.06
Non-fatal MI 8 (9%) 10 (13%) 18 (11%) 0.43
TLR 7 (8%) 10 (13%) 17 (10%) 0.26
Restenosis ‡
50%
10 (11%) 10 (13%) 20 (12%) 0.72
Thrombosis 1 (1%) 1 (1%) 2 (1%) 0.93
Stroke/TIA 1 (1%) 1 (1%) 2 (1%) 0.96
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TCT-447
Predictors and clinical implications of stent thrombosis in patients with ST-
segment elevation myocardial infarction. Insights from the EXAMINATION trial
Salvatore Brugaletta1, Manel Sabate2, Victoria Martin-Yuste3, Monica Masotti4,
Angel Cequier5, Armando Bethencourt6, Josep Gomez Lara7, Andres Iñiguez8,
Antonio Serra9, Rosana Hernandez-Antolin10, Marco Valgimigli11, Vicente Mainar10,
Maurizio Tespili12, Nicolas Vazquez13, Peter den Heijer14, Patrick W. Serruys15
1Clinic Thorax Institute, Barcelona, Spain, 2University of Barcelona, Barcelona, Spain,
3Hospital Clinic, Barcelona, Spain, 4H Clinic Barcelona, Barcelona, Spain, 5Hospital
of Bellvitge, Barcelona, Spain, 6Hospital Son Espases, Palma de Mallorca, Spain,
7Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, 8Hospital de Vigo,
Vigo, Spain, 9Hospital de Sant Pau y Santa Creu, Barcelona, Spain, 10Hospital
Universitario Ramón y Cajal, Madrid, Spain, 11University Hospital of Ferrara,
Ferrara, Italy, 12University Hospital Bolognini Seriate, Bergamo, Italy, 13Hospital Juan
Canalejo, A Coruña, Spain, 14Amphia Hospital Breda, Breda, NB, 15Thoraxcenter-
Erasmus University, Rotterdam, Netherlands
Background: few data are available about safety of second generation drug eluting
stents in an all-comer ST elevation myocardial infarction (STEMI) population. We
sough to investigate the predictors and clinical implications of 1-year stent thrombosis
(ST) in patients with STEMI, included the EXAMINATION trial.
Methods: TheEXAMINATION trial is an all-comer prospective, randomized1:1 controlled
trial, testing everolimus-eluting stent (EES) vs. cobalt chromium bare metal stent (BMS) in
STEMI patients. It included 1498 patients, randomized to EES (n¼751) or BMS (n¼747).
Results: At 1-year, deﬁnite/probable stent thrombosis, deﬁned according to ARC
criteria, occurred in 26 patients (1.73%), including 18 deﬁnite and 8 probable events.
The incidence of ST was lower in patients treated with EES than in those treated with
BMS (HR 0.16, 95% CI 0.03 – 0.29, p¼0.017). Patients with ST have higher 1-year
rates of cardiac death (30.8% vs. 2.5%, p<0.001), myocardial infarction (30.8% vs.
0.5%, p<0.001) and target vessel revascularization (65.4% vs. 4.2%, p<0.001)
compared with those without. Independent predictors of 1-year deﬁnite/probable ST
were BMS implantation at the index procedure (HR 3.41,95% CI 1.35–8.60), ST
segment resolution of at least 70% in the EKG post-PCI (HR 0.30,95% CI 0.13–0.70)
and Killip class on admission (HR 2.57,95% CI 1.70–3.90).
Conclusions: ST had low frequency in the ﬁrst year after implantation of EES/BMS in
STEMIpatients,but it is associatedwithadverseevents.BMSimplantation, lackofST-segment
resolution and high Killip class on admission were independent predictors of 1-year ST.
TCT-448
Long-Term Clinical Results Of SeQuent Please Paclitaxel-Coated Balloon
Angioplasty For The Treatment Of In-Stent Restenosis
Javier Benezet1, Ignacio Sanchez-Perez1, Fernando Lozano1, Felipe Higuera1,
Natalia Pinilla1, Yasser Hessein1
1Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
Background: Paclitaxel-coated balloons (PCB) have been proven to be effective for the
treatment of coronary in-stent restenosis (ISR) after bare-metal stent (BMS) or drug-eluting
stent (DES) implantation. This study aims to evaluate the long-term safety and efﬁcacy of
the second-generation SeQuent Please PCB in coronary ISR in routine real-world practice.
Methods: BetweenMay 2009 and April 2011, all consecutive patients with ISR lesions
treated with the SeQuent Please PCB at our institution were prospectively included.
Patients were followed up for 24 months by clinical observation. The primary endpoint
was the clinically driven target lesion revascularization (TLR) rate at 24 months. The
secondary endpoint was the rate of major adverse cardiac events (MACE: deﬁned as
a composite of cardiac death, myocardial infarction, and TLR) at 24 months.
Results: 48 patients with 52 ISR lesions (30 BMS, 22 DES) were included. Mean age
was 66.212.3 years. 75 % were male and 50 % were diabetics. The majority of
patients presented with stable angina (63.5%). The target lesion was mainly located in
the right coronary artery (46.1%) and the left anterior descending coronary artery
(42.3%). The mean reference vessel diameter was 3.00.5 mm and the mean target
lesion length was 21.46.8 mm.Procedural success was 100 %. Coronary dissection
occurred in 1 patient (1.9 %), requiring additional stent implantation. Follow-up rate
was 94.2 %. The TLR rate was 5.8 % after 24 months. Cumulative MACE at 24
months was 9.6 %, with 1.9 % cardiac death and 1.9 % myocardial infarction. No
vessel thrombosis was documented. The TLR rate did not differ for PCB angioplasty
for BMS-ISR compared with DES-ISR (3.3% vs. 9.1%, p¼0.38). Baseline lesion
characteristics and procedural data did not differ except for a longer lesion length for
BMS-ISR compared with DES-ISR (25.4 5.1 mm vs. 19.76.9 mm, p¼0.008).B138 JACC Vol 62/18/Suppl B j October 27–November 1, 20Conclusions: Treatment of coronary ISR with the second-generation SeQuent Please
PCB provides good clinical outcomes demonstrated by the low TLR rate and low
MACE rates at long-term follow-up.
TCT-449
COMPARISON OF PACLITAXEL-ELUTING BALLOONS WITH DRUG-
ELUTING STENTS FOR TREATMENT OF IN-STENT RESTENOSIS: A
RETROSPECTIVE ANALYSIS OF AN ALL-COMERS COHORT
Guillaume Marquis Gravel1, Nicolas Noiseux1, François Gobeil1,
Louis-Mathieu Stevens1, Samer Mansour1
1University of Montreal, Montreal, Quebec
Background: The optimal treatment strategy for coronary in-stent restenosis (ISR) is
unclear. Drug-eluting balloons (DEB) offer an alternative to drug-eluting stents (DES)
by avoiding risks of stent thrombosis, and by lowering the risks of restenosis asso-
ciated with standard balloon angioplasty and bare-metal stents. The objectives were to
compare clinical outcomes of DEB versus second-generation DES for the treatment of
ISR. The hypothesis was that DEB and DES would provide similar outcomes.
Methods: FromDecember 2009 toNovember 2012, 102 coronary ISRwere treatedwith
a paclitaxel-eluting balloon in all-comer patients in a Canadian tertiary center. The
comparator group consisted of a random sample of 100 patients with ISR treated with
a second-generation DES in the same time period. Data was collected frommedical ﬁles
and telephone interviews. Mean follow-up was 169 months (222 patient-years).
Baseline characteristics were similar between both groups (mean age: 6511 [p¼0.91];
28%women [p¼0.69]).Diabeteswas present in 45%of patients (p¼0.79). Indication for
revascularization was non-ST-elevation acute coronary syndrome in 71% of cases in the
DEB group as compared to 73% in the DES group (p¼0.37).
Results: The composite clinical outcome of MACE (death from any cause, non-fatal
myocardial infarction, or clinically-driven target-lesion revascularization) occurred in
26% of patients in the DEB group, compared to 24% in the DES group (p¼0.80).
Freedom from MACE was similar between both groups after adjustment for con-
founding factors. Secondary outcomes are shown in the Table.
Conclusions: DEB appears as a safe and effective treatment for ISR as compared to
second-generation DES. Our data suggest that clinical outcomes following revasculari-
zationwith bothdevices are similar.Long-termclinical outcomes following ISR treatment
with a DEB compared to second-generation DES remain to be prospectively studied.TCT-450
PREDICTORS OF ANGIOGRAPHIC OUTCOMES FOLLOWING IN-STENT
RESTENOSIS TREATMENT WITH PACLITAXEL-ELUTING BALLOONS
AND SECOND-GENERATION DRUG-ELUTING STENTS.
Guillaume Marquis Gravel1, François Gobeil1, Nicolas Noiseux1,
Louis-Mathieu Stevens1, Samer Mansour1
1University of Montreal, Montreal, Quebec
Background: Success of in-stent restenosis (ISR) treatment depends on angiographic
lesion characteristics and co-morbidities. The optimal treatment option for ISR
between drug-eluting balloons (DEB) or drug-eluting stents (DES) is not well known.
The objectives were to assess risk factors for adverse outcomes following ISR treat-
ment, and to evaluate the use of DEB in this setting.
Methods: Multivariate binary logistic regression was performed to assess predictors
of treatment success following ISR treatment in a cohort including 102 patients treated
with paclitaxel-eluting balloons and 100 random patients treated with a second-
generation DES between December 2009 and November 2012 in a Canadian tertiary
center (mean follow-up: 169 months; mean age: 6511 years). The effect of using
a DEB was adjusted for angiographic and clinical confounders. Indication for
revascularization was non-ST-elevation acute coronary syndrome in 145 cases (72%).
Lesion localization was similar in both groups (p¼0.45): 4% left main, 33% LAD,
27% circumﬂex, and 37% RCA. ISR pattern was focal in 62% of patients in the DEB
group, compared to 46% in the DES group (p¼0.02).
Results: Compared to diffuse, proliferative or occlusive lesions, a focal ISR was
a protective factor against death (OR¼0.2; p¼0.01), and target-lesion revasculariza-
tion (TLR) (OR¼0.3; p¼0.04), but not against MACE (death, non-fatal myocardial
infarction [MI], and TLR) (p¼0.29), MI (p¼0.95), or 50% restenosis (p¼0.19).
DEB/DES length was associated with MACE (OR¼1.0; p¼0.03), and death
(OR¼0.9; p¼0.001), but not with TLR, MI, and 50% restenosis (p>0.05 each).
DEB/DES diameter was associated with none of these outcomes (p>0.05 each).
Presence of chronic kidney disease (CKD) was the only identiﬁed independent risk13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
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variate logistic regression adjusting for CKD, DEB/DES length, and focal ISR, DEB
was not associated with MACE (OR¼0.9; p¼0.71) or death (OR¼1.7; p¼0.44).
Conclusions: Chronic kidney disease is an independent predictor of adverse outcomes
following percutaneous treatment of ISR. When adjusted for confounders, DEB and
DES are associated with similar outcomes in this setting.
TCT-451
Impact of Stent Recoil and Fracture in RCA Ostium Restenosis Following
Stainless Steel or Cobalt Chromium Drug-Eluting Stent Implantation: A Serial
Angiographic and IVUS Study
Atsushi Hirohata1, Eiki Hirose1, Tohru Ohe1, Ryo Yoshioka1
1The Sakakibara Heart Institute of Okayama, Okayama, Japan
Background: PCI procedure of RCA ostium stenosis is still a challenging issue due to
high stent restenosis rate, possibly due to mechanical stress. However, mechanisms of
restenosis following cobalt-chromium everolimus-eluting stent (EES) or stainless steel
biolimus-eluting stent (BES) implantation have not been well clariﬁed.
Methods: Sixty-fourRCAostium restenosis cases after 2ndgenerationDES (40EESand
24 BES) were retrospectively analyzed. Serial (post initial stent and follow-up as revas-
cularization) angiographic and IVUS evaluation were performed. In quantitative angio-
graphic analysis (QCA), incidence of stent fracture (deﬁned as complete separation of the
stent segments and/or the absence of a stent strut on magniﬁed ﬂuoroscopic image), and
partial (only one of the inner or outer struts was separated) and complete (both the inner
and outer struts were disconnected) fracture type were evaluated. In IVUS, serial changes
ofminimum lumen and stent area (SA), and degree of stent recoil atminimum lumen area,
deﬁned as (follow-up SA - baseline SA / baseline SA*100), were also measured.
Results: Average follow-up phase was 1410-months. Angiographic and IVUS
morphometric parameters were similar in both groups at baseline. Signiﬁcant lumen
narrowingwas observed from baseline to follow-up in both groups (10.24.6 to 2.52.0,
10.75.4 to 2.42.3 mm2 in minimum lumen area, EES vs. BES, p<0.01 from baseline
to follow-up for all). Stent fracturewasmore frequently observed inBES than EES (85 vs.
8%, p<0.01). In addition, complete fracturewas highly observed inBES (29%) compared
to EES (2%, p<0.05). In contrast, signiﬁcant stent recoil was observed in EES only
(11.85.7 to 9.05.4 mm2, p<0.01 from baseline to follow-up for EES, 11.64.8 to
11.33.4 mm2, p¼ns for BES, and degree of stent recoil was signiﬁcantly larger in EES
than BES (23.8 vs. 2.6%, p<0.05). Additionally, there was only 1 BES and no EES case
that both stent fracture and signiﬁcant recoil, resulting in stent restenosis, was observed.
Conclusions: Stent fracture appears to be the major cause of RCA ostium restenosis
after stainless steel BES, whereas stent recoil seem to be associated with restenosis
after cobalt-chromium EES.
TCT-452
A retrospective analysis of the incidence and predictors of new generation drug-
eluting stent fracture following percutaneous coronary intervention
Dong-Kie Kim1, Guang-Won Seo1, Pil Sang Song1, Ki-Hun Kim1, Sang-Hoon Seol1,
Yeo-Jeong Song2, Han-Young Jin2, Jeong-Sook Seo2, Jae-Sik Jang2, Tae-Hyun Yang2,
Dae-Kyeong Kim2, Dong-Soo Kim2, Ung Kim3, Hyuk-Jun Yoon4, Doo-Il Kim1
1Inje University Haeundae Paik Hospital, Busan, Korea, Republic of, 2Inje University
Busan Paik Hospital, Busan, Korea, Republic of, 3Yeungnam University Medical
Center, Daegu, Korea, Republic of, 4Keimyeong University Dongsan Hospital,
Daegu, Korea, Republic of
Background: Stent fracture (SF) is one of the complications after percutaneous
coronary intervention (PCI), although it is not often. To date many data on ﬁrst
generation drug-eluting stent (DES) fracture were published. However study on
second generation DES fracture is rare. The aim of this study was to assess the
predictors of second generation DES fracture.
Methods: From March 2010 to August 2012, a total of 1032 patients with 1283 lesions
who underwent successful implantation with second generation DES at Inje University
HaeundaePaikHospitalwere followed prospectively.Among them, 369 patients (35.7%)
with 476 (37.1%) lesions who underwent follow-up coronary angiography (CAG) 6 to 12
months after initial procedure, irrespective of clinical symptoms, were performed.
Results: SF was identiﬁed in 45 of 1032 patients (4.36%) and 51 of 1283 lesions
(3.82%). The patients were divided into SF group and non-SF group. The most
prevalent vessel of SF was the left anterior descending artery (24 lesions, 47.1%),
followed by the right coronary artery (16 lesions, 31.4%). Most lesions were classiﬁed
as type B2 (15 lesions, 29.4%) or type C (22 lesions, 43.2%). All implanted stents
were the second generation DES such as everolimus-eluting stents (17 stents, 33.3%),
zotarolimus-eluting stents (12 stents, 23.5%) and biolimus-eluting stents (10 stents,
19.7%). Compared with non-SF group, SF group was more likely to have stent
overlap (52.4% vs. 22.4%; p<0.001) and peri-procedural myocardial infarction
(32.6% vs. 12.1%; p<0.001). On multivariate logistic regression analysis, stent
overlap (odds ratio 3.45, 95% conﬁdence interval 1.66-7.17, p<0.001), Biolimus-
eluting stents (odds ratio 6.17, 95% conﬁdence interval 2.19, p<0.001), stent length
(odds ratio 1.07, 95% conﬁdence interval 1.02-1.13, p¼0.009), and peri-procedural
MI (odds ratio 3.14, 95% conﬁdence interval 1.36-7.23, p ¼0.007), were identiﬁed as
independent predictors for fracture of second generation stent.
Conclusions: The incidence of stent fracture in the second generation DES was
3.82%. The biolimus-eluting stent, overlapping stent, peri-procedural MI, and long
stent length are signiﬁcant determinants of stent fracture in the second generation.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-453
Multiple Predictors of In-Stent Restenosis with Clinical Presentation of Acute
Coronary Syndrome After Drug-Eluting Stent Implantation
Soon Jun Hong1, Chul-Min Ahn2, Do-Sun Lim1, Jae Hyoung Park1, Cheol Woong Yu3
1Korea University Anam Hospital, Seoul, Korea, Republic of, 2Korea University,
Seoul, Korea, Republic of, 3Sejong General Hospital, Bucheon, Kyeong-gi
Background: Although in-stent restenosis (ISR) after drug-eluting stent (DES) is
perceived to be a benign phenomenon, some patients with ISR showed clinical presen-
tation of acute coronary syndrome (ACS). We sought to identify parameters inﬂuencing
the likelihood of restenosis with clinical presentation of ACS after DES implantation.
Methods: Stented patients (n¼3,817) with DESs were retrospectively reviewed for
inclusion in the study from theKoreaUniversity PCIDatabase Registry. From this database,
age and sex-matched 302 patients (7.9%) with ISR were assigned to either the Stable ISR
group (n¼156) or the ACS ISR group (n¼146). Predictors of coronary restenosis with
clinical presentation of ACS were identiﬁed with Cox regression analyses.
Results: The rate of risk factors such smoking, hypertension, and diabetes were similar
between the 2 groups; moreover, the use of medications at baseline did not differ
signiﬁcantly between the 2 groups. More patients in the ACS ISR group showed two
vessel diseases (n¼70 [47.9%] vs. n¼44 [28.2%], P¼0.028, respectively). No signiﬁ-
cant differences in ISR pattern were noted between the 2 groups during the follow-up
angiogram. Follow-up MMP-2 level was signiﬁcantly higher in the ACS ISR group
when compared to the Stable ISRgroup (66,639+/-12,519 vs. 57,386+/-2,423, P¼0.011,
respectively). Age (Hazard ratio [HR], 1.13; 95% conﬁdence interval [CI], 1.02 to 1.26;
P¼0.024), diabetes (HR, 6.80; 95% CI, 1.16 to 39.9; P¼0.034), the use of aspirin (HR,
0.005; 95% CI, 0.001 to 0.760; P¼0.039), clopidogrel (HR, 0.010; 95% CI, 0.001 to
0.162; P¼0.001), ACE inhibitor (HR, 0.210; 95%CI, 0.003 to 0.515; P<0.001), the use
ofﬁrst generationDES (HR, 1.130; 95%CI, 1.030 to 1.260; P¼0.001), andMMP-2 level
(HR, 1.120; 95% CI, 1.001 to 1.190; P¼0.004) during follow-up were signiﬁcant
predictors of ISR with clinical presentation of ACS during the 3-year follow-up.
Conclusions: In the era of DES, older age, diabetes, the use of ﬁrst generation DES,
and increased MMP-2 levels were signiﬁcant predictors of ISR with clinical presen-
tation of ACS. In contrast, the use of aspirin, clopidogrel, high-dose statin, and ACE
inhibitor prevented ISR with clinical presentation of ACS.
TCT-454
Incidence and Clinical Impact of Stent Fracture After the Nobori Biolimus-
Eluting Stent Implantation
Shoichi Kuramitsu1, Masashi Iwabuchi1, Takenori Domei1, Kaoru Goya1,
Kensuke Ohe1, Takashi Hiromasa1, Yohei Kobayashi1, Takashi Morinaga1,
Makoto Hyodo1, Shinichi Shirai1, Koyu Sakai1, Kenji Ando1, Hiroyoshi Yokoi1,
Masakiyo Nobuyoshi1
1Kokura Memorial Hospital, Kitakyushu, Japan
Background: Stent fracture (SF) after drug-eluting stent implantation has recently
became an important concern. However, the incidence and clinical impact of SF after
the Nobori biolimus-eluting stent (BES) remains unclear.
Methods: A total of 1031 patients with 1407 lesions undergoing BES implantation
and follow-up angiography 6 to 9 months after index procedure were analyzed. SF
was deﬁned as complete or partial separation of the stent, as assessed by plain ﬂuo-
roscopy, intravascular ultrasound, or optical coherence tomography during follow-up.
We assessed the rate of SF and major adverse cardiac events (MACE), deﬁned as
cardiac death, myocardial infarction, stent thrombosis, and clinically driven target
lesion revascularization (TLR) within 9 months.
Results: SF was observed in 58 of 1407 lesions (4.1%) and 57 of 1031 patients (5.5%).
Lesions with hinge motion (odd ratio [OR], 6.15; 95% conﬁdence interval [CI], 3.40-
11.46; p<0.001), tortuosity (OR, 3.12; 95% CI, 1.46-7.31; p¼0.003), or overlapping
stents (OR, 2.66; 95% CI, 1.23-5.81; p¼0.013) were independent predictors of SF. The
MACE rate within 9months were signiﬁcantly higher in the SF group than in the non-SF
group (28.1% vs. 4.6%, p<0.001). The rate of TLR was signiﬁcantly higher in the SF
group than in the non-SF group (28.0% vs. 4.1%, p<0.001), whereas the rate of
myocardial infarction and stent thrombosis were not different between the 2 groups
(1.8% vs. 1.0%, p¼0.61; 1.8% vs. 0.9%, p¼0.53, respectively).acts/POSTER/In-stent Restenosis and Stent Thrombosis B139
